NLS Pharmaceutics Ltd. — Investor Relations & Filings
Filings indexed
360
across all filing types
Latest filing
2026-04-30
Regulatory Filings
Country
US
United States of America
Listing
US
NLSP
NLS Pharmaceutics Ltd. is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for patients with rare and complex central nervous system (CNS) disorders. The company's primary focus areas include sleep disorders, neurodegenerative diseases, and attention-deficit/hyperactivity disorder (ADHD). Its lead product candidates are Quilience, a proprietary extended-release formulation of mazindol for the treatment of narcolepsy, and Nolazol for ADHD. NLS Pharmaceutics is also advancing its pipeline with additional assets, such as the AEX-6xx series, to address other CNS-related conditions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-30 | English | |
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-20 | English | |
| 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-01 | English | |
| 6-K Filing | 2026-02-12 | English | |
| 6-K Filing | 2026-01-29 | English | |
| REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-12 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 39082389 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-30 | English | ||
| 34690932 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-20 | English | ||
| 33150227 | 6-K - NewcelX Ltd. (0001783036) (Filer) | 2026-04-01 | English | ||
| 31695679 | 6-K Filing | 2026-02-12 | English | ||
| 31695816 | 6-K Filing | 2026-01-29 | English | ||
| 13193183 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-12 | English | ||
| 13193185 | REPORT OF FOREIGN PRIVATE ISSUER | 2026-01-05 | English | ||
|
2025
8 filings
| |||||
| 13193187 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-12-11 | English | ||
| 13193186 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-20 | English | ||
| 13193188 | Regulatory Filings 2025 | 2025-11-19 | English | ||
| 13193189 | Regulatory Filings 2025 | 2025-11-19 | English | ||
| 13193190 | REPORT OF FOREIGN PRIVATE ISSUER | 2025-11-17 | English | ||
| 13193191 | Major Shareholding Notification 2025 | 2025-11-14 | English | ||
| 13193192 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
| 13193193 | Major Shareholding Notification 2025 | 2025-11-13 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BioInfra Life Science Inc.
Develops multi-biomarker blood tests for early cancer scree…
|
266470 | KR | Professional, scientific and te… |
|
Biomark Diagnostics Inc.
Oncology liquid biopsy diagnostics using metabolomics and A…
|
BUX | CA | Professional, scientific and te… |
|
Biomind Labs
Developing novel pharmaceutical drugs for patients with neu…
|
BMND | CA | Professional, scientific and te… |
|
BioNexus Gene Lab Corp
Develops gene-based diagnostics for early detection of dise…
|
BGLC | US | Professional, scientific and te… |
|
Biophytis S.A.
Clinical-stage biotech developing therapeutics for age-rela…
|
ALBPS | FR | Professional, scientific and te… |
|
BioRestorative Therapies, Inc.
Develops adult stem cell therapies for degenerative disc an…
|
BRTX | US | Professional, scientific and te… |
|
BioSenic SA
Develops therapies for autoimmune diseases, inflammation, a…
|
BIOS | BE | Professional, scientific and te… |
|
BIOTECH
A biotechnology group offering preclinical services, intein…
|
BST | ES | Professional, scientific and te… |
|
BIOTRON LIMITED
Clinical-stage developer of small molecule antiviral drugs …
|
BIT | AU | Professional, scientific and te… |
|
BioVaxys Technology Corp.
Clinical-stage biopharma developing novel immunotherapy ass…
|
BIOV | CA | Professional, scientific and te… |
NLS Pharmaceutics Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35193/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35193 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35193 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35193 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35193}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for NLS Pharmaceutics Ltd. (id: 35193)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.